Pharmacogenomics (PGx): Field studying genotype impact on drug absorption·metabolism·response. Core reason why same drug-dose has different effects·side effects per person.

Same drug, same dose, but some respond and some don’t. Some suffer side effects, some are fine. The decisive variable is genotype. PGx quantifies this scientifically, and by 2026 it’s part of clinical guidelines.

What it is

PGx = pharma + genomics. Genes participate in drug absorption·metabolism·target binding·excretion. Some genotypes metabolize fast, some slow. Some bind targets strongly, some don’t.

Core gene categories:

CYP enzymes (cytochrome P450): Drug metabolism. CYP2D6·CYP2C19·CYP3A4
Receptor genes: Drug targets. VDR(vitamin D)·ESR1(estrogen)·DRD2(dopamine)
Transporter genes: Drug movement. SLCO1B1·ABCB1
Coagulation genes: Warfarin metabolism. VKORC1·CYP2C9

CYP2D6 — Most famous PGx case

CYP2D6 metabolizes 25% of prescription drugs. SSRIs, codeine/tramadol, antiarrhythmics, tamoxifen.

4 metabolizer phenotypes:

Poor metabolizer (PM): Nearly 0 activity. ↑ drug levels → ↑ side effects
Intermediate metabolizer (IM): Low activity
Normal metabolizer (NM): Standard
Ultra-rapid metabolizer (UM): Very ↑ activity. Fast breakdown → ↓ effect

Ethnic distribution:

Asian: PM 1~2%, UM 1~3%
White: PM 5~10%, UM 1~5%
Ethiopian: UM 29% (unique case)

Clinical application:

Codeine: UM → morphine overproduction → respiratory depression risk. FDA restricts <12 yrs post-surgery
Tamoxifen: PM → ↓ endoxifen production → ↓ effect
SSRI: PM → ↑ side effects

VDR Genotype — L69 Tufts D2d Case

JAMA Network Open 2026.4.23 — D2d post-hoc analysis:

Vitamin D supplement + diabetes prevention
VDR genotype (FokI·BsmI·TaqI) analysis
~70% patients: supplement → diabetes prevention (HR 0.69)
~30% patients: VDR variant → no effect

VDR (Vitamin D Receptor): Receptor binding vitamin D. Genotype determines signal efficiency.

4 main SNPs:

FokI: Protein length differences. ff form ↓ efficiency
BsmI/ApaI/TaqI: mRNA stability. BB form ↑ efficiency
Cdx2: Transcription activity. Intestinal absorption

Clinical meaning:

Vitamin D deficiency + VDR variant → ↑ osteoporosis·diabetes·cancer risk
VDR test → personalized vitamin D dosing

CYP2C19 — Antiplatelet·SSRI

CYP2C19: Clopidogrel(antithrombotic), omeprazole(antacid), SSRI metabolism

Phenotypes:

PM (Korean 13~23%, white 2~5%): Clopidogrel activation ↓ → ↑ cardiovascular events
UM (Korean 1~2%): Omeprazole ↓ effect → insufficient acid suppression

Guidelines:

FDA·CPIC: Stent patients CYP2C19 test → PM = prasugrel/ticagrelor alternative

VKORC1·CYP2C9 — Warfarin

Warfarin dosing is hard. Too little = clot, too much = bleed.

VKORC1: Vitamin K cycle enzyme. Variant → ↓ warfarin dose CYP2C9: Warfarin metabolism. *2/*3 variants → ↓ dose

Warfarin Dosing Algorithm: VKORC1 + CYP2C9 + age·weight·aspirin → initial dose prediction. ↓ trial and error

SLCO1B1 — Statin Muscle Side Effects

SLCO1B1: Liver uptake transporter. Variant(c.521T>C) → ↑ statin blood levels → ↑ myalgia·rhabdomyolysis risk

FDA label: Simvastatin 80mg → SLCO1B1 variant ↑ risk → label warning

PGx Testing — Korean Availability

Insurance:

TPMT(azathioprine): Pre-leukemia·autoimmune
UGT1A1(irinotecan): Pre-colorectal cancer
HLA-B*1502(carbamazepine): Pre-epilepsy drug (Stevens-Johnson)
DPYD(5-FU): Anticancer side effects

Out-of-pocket:

CYP2D6/CYP2C19 panel: 300~500K KRW
Integrated PGx panel (50~100 genes): 500K~1.5M KRW
Some health checkup centers·local clinics

Effects — First daily entry of precision medicine

Clinical:

↓ side effects 30~50%
↑ first drug selection accuracy
↓ cost (trial/error·revisit)

Daily:

Depression med doesn’t work → SSRI 4 trials (3~6 mo) → CYP2D6/2C19 test for first selection
Vitamin D not working → VDR test predicts effect
Warfarin hard to dose → VKORC1/CYP2C9 for initial optimization

Limits — Only some drugs·some genes yet

Unresolved:

Not all drugs have PGx data
Multifactorial influences (1 gene doesn’t explain all)
Environment·drug interactions
Epigenetic effects

But clear domains:

~10~20 above gene·drug combos = guideline-established
First gateway of precision medicine daily entry

FAQ

Q. Does general PGx testing make sense for laypeople? A. Yes if family history of drug side effects·antidepressants·anticoagulants·statins. Results interpretation requires pharmacist·doctor consultation.

Q. Are PGx results valid for life? A. Genotype doesn’t change, so yes. But new drugs·guidelines need periodic updates.

Q. If VDR test, skip vitamin D? A. Vitamin D deficiency itself is risky. VDR variant → dose adjust·other strategies (K2 combo·sun).

Q. PGx vs 23andMe difference? A. 23andMe = ancestry·general risk. PGx = drug response specialized. Some SNP overlap but report·clinical utility differ.

Q. Best timing for PGx test? A. Just after chronic disease diagnosis·before new drug·current side effects·pregnancy planning. Not for emergencies (time required).

CYP enzymes: Drug metabolism P450 family
SNP: Single nucleotide polymorphism. Genetic variant unit
HLA: Immune-related genes. Drug allergy prediction
TDM: Therapeutic drug monitoring. PGx complementary

Conclusion

PGx is no longer academic. CYP2D6·CYP2C19·VKORC1·VDR·SLCO1B1 clinical applications are established, Korean insurance·OOP testing available. L69 Tufts D2d post-hoc shows even vitamin D splits by PGx. Same drug = same effect era is over. Time for pharmacist·doctor to see PGx test results together.

Pharmacogenomics (PGx) Precision Medicine — Same Drug, Different Effect. Genotype Decides Drug Response